MARTINSRIED, Germany I May 6, 2013 I Proteros biostructures GmbH today announced thesuccessful completion of an integrated lead discovery collaboration with Eisai Co., Ltd. Based on Proteros’ structure guided discovery platform, various series of Lead Compounds were developed within a period of 10 months.
The developed compound series showed single digit nanomolar Kd values, as well as optimized binding kinetics and kinetic selectivity. Hits were identified out of the Proteros fragment library and the optimization process was driven by high quality protein crystallography as well as kinetic and thermodynamic profiling and the seamless interactions between Eisai and Proteros medicinal and computational chemists.
Dr. Lars Neumann, Vice President Discovery Projects and Project Manager stated: “We are very satisfied with the course of the project and are pleased to deliver the lead compound series to our partner Eisai Co., Ltd. We look forward to contributing further to the success of the Eisai research pipeline using our unique technology platform.”
About Proteros:
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead discovery. The platform allows structure accelerated Lead Discovery. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.
About Eisai:
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.
SOURCE: Proteros biostructures
Post Views: 292
MARTINSRIED, Germany I May 6, 2013 I Proteros biostructures GmbH today announced thesuccessful completion of an integrated lead discovery collaboration with Eisai Co., Ltd. Based on Proteros’ structure guided discovery platform, various series of Lead Compounds were developed within a period of 10 months.
The developed compound series showed single digit nanomolar Kd values, as well as optimized binding kinetics and kinetic selectivity. Hits were identified out of the Proteros fragment library and the optimization process was driven by high quality protein crystallography as well as kinetic and thermodynamic profiling and the seamless interactions between Eisai and Proteros medicinal and computational chemists.
Dr. Lars Neumann, Vice President Discovery Projects and Project Manager stated: “We are very satisfied with the course of the project and are pleased to deliver the lead compound series to our partner Eisai Co., Ltd. We look forward to contributing further to the success of the Eisai research pipeline using our unique technology platform.”
About Proteros:
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead discovery. The platform allows structure accelerated Lead Discovery. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.
About Eisai:
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.
SOURCE: Proteros biostructures
Post Views: 292
